Fig. 2

Serum urate lowering efficacy of febuxostat according to subtype of hyperuricemia. A Proportion of participants with SU < 6.0 mg/dL at weeks 4, 8, and 12 using per-protocol analysis. B Proportion of SU < 5.0 mg/dL at weeks 4, 8, and 12 using per-protocol analysis. C Proportion of participants with SU < 6.0 mg/dL at weeks 4, 8, and 12 using intention-to-treat analysis. D Proportion of SU < 5.0 mg/dL at weeks 4, 8, and 12 using intention-to-treat analysis. E Proportion of participants requiring febuxostat dose escalation to 40 mg daily. PP per-protocol, ITT intention-to-treat. Asterisk indicates compared with the renal overload subtype, P < 0.05, number sign indicates compared with the renal underexcretion subtype, P < 0.05